• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 29th October 2019

Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries

New research by the Office of Health Economics (OHE) concludes the proposed International Price Index effectively outsources pharmaceutical policy decisions to countries that “give the government a central role” vs. the U.S.’ greater reliance on the private market. In an…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

New research by the Office of Health Economics (OHE) concludes the proposed International Price Index effectively outsources pharmaceutical policy decisions to countries that “give the government a central role” vs. the U.S.’ greater reliance on the private market.

In an effort to cap the U.S. price of drugs, The Trump Administration has proposed using an International Pricing Index (IPI), which seeks to set prices for physician-administered drugs in Medicare to the average prices paid in a collection of similar countries [1].

One criticism of the proposal is that the basket of countries suggested are not similar enough to the U.S. in terms of demographics, economic prosperity, the relative market orientation of their healthcare systems, and therefore their preferences for health.

A variant has been proposed that replaces Canada, Finland, Greece, Italy, Spain, Sweden, and the United Kingdom with Denmark, the Netherlands, Singapore, and Switzerland on the basis that they are “the most market-oriented health care systems anywhere in the industrialized world [2].”

However, new analysis [3] by OHE finds that the countries that have been proposed as market-based instead “differ markedly from the U.S. and give the government a central role in purchasing medicines, in contrast to the greater reliance on the private market seen in the U.S.”

OHE has analysed the comparability of the proposed countries to the U.S. and considered the larger question of whether the proposed IPI is an appropriate approach to setting drug prices in the U.S. 

It finds that within these four countries drug prices are typically set by a single, monopsonistic payer rather than through one-on-one negotiations between insurers and manufacturers as in the U.S.  As part of these centralised negotiations, payers have not always reimbursed drugs that have been approved as safe and effective: availability of approved drugs in these countries ranges between 83% and 74%, compared to 100% in the U.S. Furthermore, value-based pricing frameworks are used in setting prices in the Netherlands and Denmark, meaning that the public’s willingness-to-pay for health in these countries would inform drug prices in the U.S.

OHE concludes that “If the intent is to use ‘market orientation’ as a sifting criterion for potentially comparable countries, then it requires more intellectual clarity than is arguably given to it…,” and “A central monopsonistic payer negotiating or regulating medication prices is not an obvious component of a ‘market-oriented’ approach to drug pricing in a healthcare system.”

OHE also concludes that the general market orientation of a health system is not in itself a sufficient criterion for inclusion in a market-based price index.  Differences in macro-level demographics and health system organisation also means that the proposed countries have limited comparability with the U.S.  More generally, any international reference pricing effectively outsources the valuation of drugs and innovation to other countries and is a poor substitute for a US-based approach to valuing drugs that incorporates US preferences around health. 

This study was funded by PhRMA through OHE Consulting Ltd, a subsidiary of the Office of Health Economics.

Contact Details

Office of Health Economics
7th Floor Southside
105 Victoria Street
London, UK
SW1E 6QT

ohegeneral@ohe.org

For interview requests, please contact atowse@ohe.org

Notes to Editors:

 [1] The Trump Administration proposal would compare the U.S. to the other G7 countries (Canada, France, Germany, Italy, Japan, UK) plus countries in Germany’s International Reference Pricing basket, excluding Denmark and the Netherlands for lack of data, giving a total of 16 comparator countries. See: Centers for Medicare & Medicaid Services, International Pricing Index Model for Medicare Part B Drugs, 83 Fed. Reg. 54546 (Oct. 30, 2018)

[2] Roy, A. What Medicare Can Learn From Other Countries on Drug Pricing. Market-based policies from countries like Denmark and Singapore can make medicines more affordable in the U.S. (Jan 18, 2019). Available at: https://freopp.org/what-medicare-can-learn-from-other-countries-on-drug-pricing-bf298d390bc5

[3] Towse, et al. A Market-based International Reference Price Index: Solution or Contradiction? (Sep 13, 2019). Available at: https://www.ohe.org/news/market-based-international-reference-price-index-solution-or-contradiction

About OHE:

Founded in 1962, the Office of Health Economics (OHE) is the world’s oldest health economics research organisation. A non-profit charity based in London UK but operating globally, OHE’s mission is to support better health care policies by providing insightful economic and statistical analyses of critical issues.

OHE Consulting Ltd., a subsidiary of OHE, was founded in 2002 and provides global, client-focused, specialised expertise on policy and strategic issues affecting the delivery of health care and the future of the pharmaceutical and life sciences industries.  OHE Consulting is dedicated to providing objective, independent advice to help our clients achieve their objectives.

 

  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
  • News
  • October 2021

We have launched OHE Bulletin, a new monthly newsletter

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!